• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Dere Willard H

    6/13/25 5:02:42 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRSN alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Dere Willard H

    (Last) (First) (Middle)
    C/O MERSANA THERAPEUTICS, INC.
    840 MEMORIAL DRIVE

    (Street)
    CAMBRIDGE MA 02139

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Mersana Therapeutics, Inc. [ MRSN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/12/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $0.36 06/12/2025 A 61,500 (1) 06/11/2035 Common Stock 61,500 $0 61,500 D
    Explanation of Responses:
    1. The award will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2026 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continuous service with the Issuer on such vesting date.
    /s/ Alejandra Carvajal, Attorney-in-Fact 06/13/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MRSN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MRSN

    DatePrice TargetRatingAnalyst
    2/6/2025Outperform
    William Blair
    11/15/2024$5.00Buy
    Citigroup
    3/19/2024$5.00Underweight → Neutral
    JP Morgan
    2/29/2024$6.00Neutral → Buy
    BTIG Research
    2/29/2024$7.00Neutral → Buy
    Guggenheim
    2/29/2024$2.00 → $7.00Neutral → Outperform
    Wedbush
    12/4/2023$1.00 → $5.00Neutral → Buy
    Citigroup
    7/28/2023$7.00 → $1.00Outperform → Neutral
    Robert W. Baird
    More analyst ratings

    $MRSN
    SEC Filings

    View All

    SEC Form 10-Q filed by Mersana Therapeutics Inc.

    10-Q - Mersana Therapeutics, Inc. (0001442836) (Filer)

    8/13/25 8:56:20 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mersana Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Mersana Therapeutics, Inc. (0001442836) (Filer)

    8/13/25 7:13:33 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mersana Therapeutics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Mersana Therapeutics, Inc. (0001442836) (Filer)

    7/24/25 8:40:38 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRSN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Alleva Lawrence M

    4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)

    6/13/25 5:15:12 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hack Andrew A. F.

    4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)

    6/13/25 5:10:40 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Dere Willard H

    4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)

    6/13/25 5:02:42 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRSN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results

    More than 45 patients enrolled in Emi-Le Phase 1 dose expansion cohorts in post-topoisomerase-1 inhibitor ADC (post-topo-1) triple-negative breast cancer (TNBC)Plan to report initial clinical data from Emi-Le expansion cohorts in second half of 2025Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the second quarter ended June 30, 2025. "During the second quarter, we were excited to

    8/13/25 7:00:00 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025

    CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the second quarter ended June 30, 2025 on Wednesday, August 13, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning. To access the call, please dial 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast of the presentation will be available on the Investors & Media section of the Mersana

    8/6/25 8:00:18 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mersana Therapeutics Announces 1-for-25 Reverse Stock Split

    CAMBRIDGE, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will implement a 1-for-25 reverse stock split of the issued shares of the company's common stock (the Reverse Stock Split), effective at 5:00 p.m. Eastern Time on July 25, 2025. The Reverse Stock Split was approved by the company's stockholders at the company's Annual Meeting of Stockholders held on June 12, 2025, with the final ratio subsequently determined by the company's Board of Directors. One of the primary go

    7/24/25 8:31:52 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRSN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Mersana Therapeutics

    William Blair initiated coverage of Mersana Therapeutics with a rating of Outperform

    2/6/25 7:08:59 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup resumed coverage on Mersana Therapeutics with a new price target

    Citigroup resumed coverage of Mersana Therapeutics with a rating of Buy and set a new price target of $5.00

    11/15/24 8:15:56 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mersana Therapeutics upgraded by JP Morgan with a new price target

    JP Morgan upgraded Mersana Therapeutics from Underweight to Neutral and set a new price target of $5.00

    3/19/24 7:51:31 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRSN
    Financials

    Live finance-specific insights

    View All

    Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results

    More than 45 patients enrolled in Emi-Le Phase 1 dose expansion cohorts in post-topoisomerase-1 inhibitor ADC (post-topo-1) triple-negative breast cancer (TNBC)Plan to report initial clinical data from Emi-Le expansion cohorts in second half of 2025Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the second quarter ended June 30, 2025. "During the second quarter, we were excited to

    8/13/25 7:00:00 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025

    CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the second quarter ended June 30, 2025 on Wednesday, August 13, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning. To access the call, please dial 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast of the presentation will be available on the Investors & Media section of the Mersana

    8/6/25 8:00:18 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

    In a release issued under the same headline earlier today by Mersana Therapeutics, Inc. (NASDAQ:MRSN), please note that there was a transcription error in the last cell of the first table. The Median OS should have been 5.7 months rather than 1.7 months. The corrected release follows: Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results Updated clinical data from Emi-Le Phase 1 dose escalation and backfill cohorts presented today at ESMO Breast Cancer 2025 ORR increased to 31% across tumor types among evaluable patients with B7-H4 high tumors receiving intermediate dosesEncouraging preliminary time-to-event data in triple-negative breast cancer (

    5/15/25 9:20:09 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRSN
    Leadership Updates

    Live Leadership Updates

    View All

    Mersana Therapeutics Announces Changes in Leadership

    Anna Protopapas to retire as President and Chief Executive Officer (CEO); will remain a member of the Board of DirectorsMartin Huber, M.D., current member of the Board of Directors, to be named President and CEOBrian DeSchuytner named Chief Operating Officer; Mohan Bala, Ph.D., named Chief Development Officer CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the retirement of Anna Protopapas, President and CEO, effective September 10, 2023, and the

    9/6/23 7:00:40 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mersana Therapeutics Provides Statement About SVB

    CAMBRIDGE, Mass., March 10, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided an update about its capital resources. A de minimis amount of Mersana's capital is currently held in a checking account at Silicon Valley Bank (SVB). The balance of the company's capital resources is held in a custodial account managed by another institution and in money market funds of institutions other than SVB. Mersana has a loan and security agreement with Oxford Finance LLC and SVB. As previously

    3/10/23 7:10:38 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mersana Therapeutics Announces Appointment of Mohan Bala, Ph.D., as SVP, Strategic Product Planning & Program Leadership

    CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Mohan Bala, Ph.D., as SVP, Strategic Product Planning & Program Leadership, effective Monday, October 25, 2021. Dr. Bala will assume strategic product planning responsibilities from Brian DeSchuytner who has been named SVP and Chief Financial Officer. Mr. DeSchuytner will continue to lead finance, business development, corporate strategy and investor relations and remain Mersana's pri

    10/25/21 8:00:00 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRSN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Mersana Therapeutics Inc.

    SC 13D/A - Mersana Therapeutics, Inc. (0001442836) (Subject)

    11/15/24 4:45:57 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mersana Therapeutics Inc.

    SC 13G/A - Mersana Therapeutics, Inc. (0001442836) (Subject)

    11/14/24 5:45:55 PM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mersana Therapeutics Inc.

    SC 13G/A - Mersana Therapeutics, Inc. (0001442836) (Subject)

    11/14/24 6:01:51 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care